1991 – to date BioPlanta GmbH
President and CEO
● Development and Manufacturing of stem cell products
● Clinical Trial and Licensing of stem cell pharmaceuticals and tissue engineered products
2017 – 2018 Bergmann AG
Chief Business Development Officer; since 12/2017 Chief Financial Officer
● General Management, budgeting and controlling
● Development of international cooperation
● Merger & Acquisition
2012 – 2017 Vita 34 AG (Frankfurt Stock Exchange, prime standard)
Chief Executive Officer
● General Management, responsible for strategy, production, new products, Research & Development, Investor Relation, shareholder attendance
● International Business Development
● Development of new products for stem cell banking (due to GMP and pharmaceutical guidelines)
● Application for pharmaceutical approvals, international accreditation